Dextech Medical AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
Study of ODX (OsteoDex) in Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Drug: ODX (Osteodex)
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- DexTech Medical AB
- Target Recruit Count
- 12
- Registration Number
- NCT06616389
- Locations
- 🇸🇪
Karolinska Universitetssjukhuset Huddinge Cancerstudieenheten M62, Stockholm, Sweden
🇸🇪Uddevalla Sjukhus, Hematologens dagvård, Uddevalla, Sweden
Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- DexTech Medical AB
- Target Recruit Count
- 55
- Registration Number
- NCT02825628
- Locations
- 🇪🇪
East Tallinn Central Hospital, Tallinn, Estonia
🇪🇪Tartu University Hospital, Tartu, Estonia
🇫🇮Tampere University Hospital, Urology Clinic, Tampere, Finland
A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- DexTech Medical AB
- Target Recruit Count
- 3
- Registration Number
- NCT02378870
- Locations
- 🇸🇪
Oncology clinic, Norrlands Universitetssjukhus, Umeå, Sweden
A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- DexTech Medical AB
- Target Recruit Count
- 28
- Registration Number
- NCT01595087
- Locations
- 🇸🇪
Oncology clinic, Skånes Universitetssjukhus i Lund, Lund, Sweden
🇸🇪Urology clinic, Södersjukhuset AB, Stockholm, Sweden
🇸🇪Oncology clinic, Norrlands Universitetssjukhus, Umeå, Sweden